

Citation for published version:

Hines, PA, Guy, RH, Brand, A, Humphreys, AJ & Papaluca-Amati, M 2020, 'Regulatory Science and Innovation Programme for Europe (ReSciPE): A proposed model', *British Journal Of Clinical Pharmacology*, vol. 86, no. 2, pp. 2530-2534. <https://doi.org/10.1111/bcp.14099>

DOI:

[10.1111/bcp.14099](https://doi.org/10.1111/bcp.14099)

Publication date:

2020

Document Version

Peer reviewed version

[Link to publication](#)

This is the peer reviewed version of the following article: Hines, PA, Guy, RH, Brand, A, Humphreys, AJ, Papaluca-Amati, M. Regulatory Science and Innovation Programme for Europe (ReSciPE): A proposed model. *Br J Clin Pharmacol.* 2019; 1– 5., which has been published in final form at <https://doi.org/10.1111/bcp.14099>. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.

University of Bath

Alternative formats

If you require this document in an alternative format, please contact:
openaccess@bath.ac.uk

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Supplementary Information

Regulatory Science and Innovation Programme for Europe (ReSciPE): a proposed model

Philip A. Hines^{1,2*}, Richard H. Guy^{1,4,5}, Angela Brand^{2,3}, Anthony J. Humphreys¹ & Marisa Papaluca-Amati¹

- 1 European Medicines Agency, Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
- 2 United Nations University - Maastricht Economic and Social Research Institute on Innovation & Technology (UNU-MERIT), Maastricht University, Boschstraat, 6211 AX Maastricht, The Netherlands
- 3 Department of International Health, Faculty of Health, Medicine and Life Sciences (FHLM), Maastricht University, Duboisdomein 30, 6229 GT Maastricht, The Netherlands
- 4 University of Bath, Centre for Therapeutic Innovation, Department of Pharmacy & Pharmacology, Claverton Down, Bath, BA2 7AY, U.K.
- 5 University of California - San Francisco (UCSF) - Stanford Center of Excellence in Regulatory Science & Innovation, Department of Bioengineering and Therapeutic Sciences, UCSF, San Francisco, CA 94158, U.S.A.

Table S1: Areas of regulatory science and innovation subjected to horizon-scanning

Science & technology	Regulatory science tools	Health threats	Environment	International regulatory science cooperation
<ul style="list-style-type: none"> * Major therapeutic areas (oncology, CNS – neurodegeneration, CNS-psychiatry, diabetes, obesity, HIV, vaccines, immunotherapy, etc.) * Gene therapy and regenerative medicine (cells and tissue-based products, novel materials) * Personalised/precision medicine and biomarkers * Methods, technologies, etc. (nanotechnology, ‘omics, disease taxonomy, digital health and wearable technology, novel manufacturing and 3-D printing) 	<ul style="list-style-type: none"> * Access pathways (PRIME, adaptive pathways, biosimilars, synergies with HTAs and payers) * Non-clinical methodology (novel models, application of 3Rs in medicines development) * Clinical methodology (modelling and simulation, extrapolation, patient-reported outcomes, new endpoints, Bayesian methods, co-acting medicinal products, novel clinical trials) * Special populations (paediatric, geriatric, pregnancy) * Risk-benefit evaluation * Big data and e-Health (real world evidence, open science, cognitive computing) * Communications (social and behavioural science) * Pharmacoepidemiology and pharmacovigilance 	<ul style="list-style-type: none"> * AMR * Emerging threats 		